Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in NTLA.

← Back to Free Index

NTLA

Analysis as of: 2026-06-21

Intellia Therapeutics, Inc.

Intellia develops in vivo CRISPR gene-editing therapies for severe diseases, led by hereditary angioedema and transthyretin amyloidosis programs.

ai biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

First Approval Could Reset the Value Curve

The case hinges on converting unusually strong HAE data into a filed, approved and reimbursed product. If that happens on schedule, the company can shift from platform discount to commercial-franchise valuation, but the path is still narrow.

Analysis

Thesis

If lonvo-z clears FDA and launches on schedule, Intellia can rerate from a cash-burning platform story into a real rare-disease franchise, with most of the 2031 value coming from HAE revenue, partial ATTR recovery and smarter platform monetization rather than blue-sky pipeline optionality.

Last Economy Alignment

AI helps discovery, trial operations and evidence generation, but Intellia still wins or loses on biology, regulatory trust and launch execution. Its value is protected by IP and clinical proof rather than software that gets commoditized.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

4.0x (from 5 most recent analyses)

Reasoning

The upside is mainly a change in what investors think they own: not just a CRISPR platform, but a commercial rare-disease company with a one-time therapy, a reusable treatment-center footprint and credible follow-on optionality. I underwrite strong HAE conversion, some ATTR recovery and selective partnering, but not a full platform moonshot.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

This is now mostly a conversion-risk story, not a pure science story. Intellia must turn strong HAE data into a completed filing, approval, payer access, center readiness and durable physician trust while rebuilding confidence in ATTR after prior holds. The good news is that software-style commoditization risk is minimal; the bad news is that regulatory permissioning and product concentration remain very real.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

Detailed Phase 3 HAELO results and simultaneous publication strengthened the case that lonvo-z can be discussed as a real launch candidate, not just a topline-data story.
Management's commercial path remains unchanged: rolling BLA is underway, completion is still targeted for 2H 2026, and a potential U.S. launch is still framed for 1H 2027.
No fresh negative ATTR development emerged in the last 7-10 days, so the main debate remains recovery of that franchise rather than a new deterioration.

Forecast update

Better HAE conviction is partly offset by the larger post-offering equity base and a stricter view of how fast a first one-time rare-disease launch scales.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.33

They are not selling software that AI makes cheap; they are trying to own a regulated, one-time medicine with hard-to-copy clinical evidence. The upside comes from controlling trusted treatment data and launch workflow, while the biggest threat is still FDA timing and safety, not AI obsolescence.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$26.63

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research